ATE159031T1 - Antigene sowie verfahren zu deren herstellung - Google Patents
Antigene sowie verfahren zu deren herstellungInfo
- Publication number
- ATE159031T1 ATE159031T1 AT90307900T AT90307900T ATE159031T1 AT E159031 T1 ATE159031 T1 AT E159031T1 AT 90307900 T AT90307900 T AT 90307900T AT 90307900 T AT90307900 T AT 90307900T AT E159031 T1 ATE159031 T1 AT E159031T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- particle
- hepatitis
- residues
- followed
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 abstract 3
- 239000011246 composite particle Substances 0.000 abstract 3
- 208000002672 hepatitis B Diseases 0.000 abstract 3
- 102100031673 Corneodesmosin Human genes 0.000 abstract 2
- 229940096437 Protein S Drugs 0.000 abstract 2
- 108010031318 Vitronectin Proteins 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 241000320412 Ogataea angusta Species 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38534289A | 1989-07-25 | 1989-07-25 | |
| US38918489A | 1989-08-03 | 1989-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE159031T1 true ATE159031T1 (de) | 1997-10-15 |
Family
ID=27010975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT90307900T ATE159031T1 (de) | 1989-07-25 | 1990-07-19 | Antigene sowie verfahren zu deren herstellung |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0414374B1 (de) |
| JP (1) | JP3069907B2 (de) |
| KR (1) | KR0181940B1 (de) |
| CN (1) | CN1080304C (de) |
| AT (1) | ATE159031T1 (de) |
| AU (3) | AU5972890A (de) |
| CA (1) | CA2021762C (de) |
| DE (1) | DE69031556T2 (de) |
| DK (1) | DK0414374T3 (de) |
| ES (1) | ES2109921T3 (de) |
| FI (1) | FI903721A0 (de) |
| GR (1) | GR3025819T3 (de) |
| HK (1) | HK1003032A1 (de) |
| HU (1) | HU216013B (de) |
| IE (1) | IE902690A1 (de) |
| IL (1) | IL95153A0 (de) |
| MA (1) | MA21911A1 (de) |
| NO (1) | NO304268B1 (de) |
| NZ (1) | NZ234615A (de) |
| PL (1) | PL168597B1 (de) |
| PT (1) | PT94791B (de) |
| SG (1) | SG48175A1 (de) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988010300A1 (en) * | 1987-06-22 | 1988-12-29 | Medico Labs Ag | Heterologous viral peptide particle immunogens |
| PL168408B1 (pl) * | 1989-08-03 | 1996-02-29 | Smithkline Beecham Biolog | Sposób wytwarzania stransformowanego mikroorganizmu PL |
| EP0491077A1 (de) * | 1990-12-19 | 1992-06-24 | Medeva Holdings B.V. | Zusammensetzung verwendbar als therapeutisches Mittel gegen chronische virale Leberkrankheiten |
| IL101653A0 (en) * | 1991-04-29 | 1992-12-30 | Merck & Co Inc | Multiple hepatitis b virus surface proteins which form particles |
| IL101651A0 (en) * | 1991-04-29 | 1992-12-30 | Merck & Co Inc | Hepatitis b virus surface proteins with reduced host carbohydrate content |
| MA22842A1 (fr) * | 1992-03-27 | 1993-10-01 | Smithkline Beecham Biolog | Procede de preparation de compositions de vaccin. |
| US6620414B2 (en) | 1992-03-27 | 2003-09-16 | Smithkline Beecham Biologicals (S.A.) | Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A |
| EP2289548A3 (de) | 1992-05-23 | 2012-08-08 | GlaxoSmithKline Biologicals S.A. | Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten |
| UA40597C2 (uk) | 1992-06-25 | 2001-08-15 | Смітклайн Бічем Байолоджікалс С.А. | Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів |
| ES2162139T5 (es) * | 1993-03-23 | 2008-05-16 | Smithkline Beecham Biologicals S.A. | Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado. |
| AT409863B (de) * | 1993-07-30 | 2002-12-27 | Immuno Ag | Hoch effiziente expression eines polypeptids, das eine modifizierte pres1-region des grossen hepatitis b-virus-antigens enthält |
| US6488934B1 (en) | 1995-02-25 | 2002-12-03 | Smithkline Beecham Biologicals S.A. | Hepatitis B vaccine |
| GB9503863D0 (en) * | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
| US5658579A (en) * | 1995-07-31 | 1997-08-19 | The Procter & Gamble Company | Cosmetic powder compositions having improved skin coverage |
| GB9623233D0 (en) | 1996-11-07 | 1997-01-08 | Smithkline Beecham Biolog | Vaccine composition |
| KR100372233B1 (ko) * | 1997-03-12 | 2003-06-11 | 주식회사 코리아나화장품 | 미백 파우더, 그의 제조방법 및 그를 함유하는 메이크업 미백 화장료 |
| US7357936B1 (en) | 1998-10-16 | 2008-04-15 | Smithkline Beecham Biologicals, Sa | Adjuvant systems and vaccines |
| BR9916893A (pt) * | 1999-01-12 | 2001-11-20 | Smithkline Beecham Biolog | Tratamento |
| FR2803599B1 (fr) * | 2000-01-06 | 2004-11-19 | Inst Nat Sante Rech Med | Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications |
| GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
| DK1648931T3 (da) | 2003-07-21 | 2011-03-07 | Transgene Sa | Multifunktionelle cytokiner |
| US7851433B2 (en) | 2003-08-13 | 2010-12-14 | Novartis Vaccines And Diagnostics, Inc. | Method of purifying TFPI and TFPI analogs |
| EP2329843A3 (de) * | 2005-04-18 | 2011-09-14 | Novartis Vaccines and Diagnostics, Inc. | Expression des Hepatitis-B-Virus-Oberflächenantigens zur Impfstoffherstellung |
| GB0522765D0 (en) * | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| BRPI0716519A2 (pt) | 2006-09-07 | 2013-10-08 | Glaxosmithkline Biolog Sa | Método para fabricar uma vacina |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| ES2657392T3 (es) | 2006-09-26 | 2018-03-05 | Infectious Disease Research Institute | Composición de vacuna que contiene un adyuvante sintético |
| WO2008043774A1 (en) | 2006-10-12 | 2008-04-17 | Glaxosmithkline Biologicals S.A. | Vaccine comprising an oil in water emulsion adjuvant |
| EP2433648A3 (de) | 2006-10-12 | 2012-04-04 | GlaxoSmithKline Biologicals S.A. | Impfstoff mit einem Öl-in-wasser-emulsionshilfsstoff |
| TW200908994A (en) | 2007-04-20 | 2009-03-01 | Glaxosmithkline Biolog Sa | Vaccine |
| KR20100017569A (ko) | 2007-05-02 | 2010-02-16 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
| PT2437753T (pt) | 2009-06-05 | 2016-11-23 | Infectious Disease Res Inst | Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos |
| CN102038948B (zh) * | 2009-10-10 | 2013-04-10 | 复旦大学 | 一种控制乙型肝炎病毒持续性感染的疫苗 |
| JPWO2011046218A1 (ja) * | 2009-10-16 | 2013-03-07 | 株式会社カネカ | 抗体を生産するハンゼヌラ・ポリモルファ、それを用いた抗体の生産方法、およびそれにより得られる抗体 |
| KR101958753B1 (ko) | 2010-04-13 | 2019-03-15 | 셀덱스 쎄라퓨틱스, 인크. | 인간 ｃｄ27에 결합하는 항체 및 이의 용도 |
| MX350795B (es) | 2011-04-08 | 2017-09-19 | Inmune Design Corp | Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares. |
| GB201105981D0 (en) | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
| CN103087933B (zh) * | 2011-11-08 | 2015-07-22 | 北京生物制品研究所 | 一种重组多形汉逊酵母菌及其制备方法 |
| LT2811981T (lt) | 2012-02-07 | 2019-06-10 | Infectious Disease Research Institute | Pagerintos adjuvanto kompozicijos, apimančios tlr4 agonistus, ir jų panaudojimo būdai |
| CN102643349B (zh) * | 2012-04-17 | 2013-12-18 | 中国医学科学院医学生物学研究所 | 携带乙肝病毒抗原表位的重组嵌合蛋白及其制备 |
| LT2850431T (lt) | 2012-05-16 | 2018-06-25 | Immune Design Corp. | Vakcinos, skirtos hsv-2 |
| EP3587455A1 (de) | 2012-10-23 | 2020-01-01 | Emory University | Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren |
| JP6426706B2 (ja) | 2013-04-18 | 2018-11-21 | イミューン デザイン コーポレイション | がん処置で使用するためのｇｌａ単剤療法 |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| KR102411781B1 (ko) | 2013-12-31 | 2022-06-22 | 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) | 단일 바이알 백신 제형 |
| EP3268037B1 (de) | 2015-03-09 | 2022-08-31 | Celldex Therapeutics, Inc. | Cd27 agonists |
| CN105797151A (zh) * | 2016-03-25 | 2016-07-27 | 汪和睦 | 一种基于重组汉逊酵母的高剂量乙型肝炎疫苗 |
| MA44723A (fr) | 2016-04-18 | 2019-02-27 | Celldex Therapeutics Inc | Anticorps agonistes se liant au cd40 humain et leurs utilisations |
| DK3458475T3 (da) | 2016-05-16 | 2022-09-12 | Access To Advanced Health Inst | Formulering, der indeholder tlr-agonist, og anvendelsesfremgangsmåder |
| JP7195147B2 (ja) | 2016-05-16 | 2022-12-23 | アクセス ツー アドバンスト ヘルス インスティチュート | Ｐｅｇ化リポソームおよび使用方法 |
| IL298227B2 (en) | 2016-06-01 | 2024-09-01 | Access To Advanced Health Inst | Nanoalum particles containing a fixing factor |
| JP2020524143A (ja) | 2017-06-15 | 2020-08-13 | インフェクシャス ディズィーズ リサーチ インスティチュート | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
| EP3678695A1 (de) | 2017-09-08 | 2020-07-15 | Infectious Disease Research Institute | Liposomale formulierungen enthaltend saponin und verwendungsverfahren |
| EP3781265A2 (de) | 2018-04-17 | 2021-02-24 | Celldex Therapeutics, Inc. | Anti-cd27- und anti-pd-l1-antikörper und bispezifische konstrukte |
| US20220016168A1 (en) | 2018-12-11 | 2022-01-20 | Celldex Therapeutics, Inc. | Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy |
| JP2022532944A (ja) | 2019-05-25 | 2022-07-20 | アクセス ツー アドバンスト ヘルス インスティチュート | アジュバントワクチンエマルジョンを噴霧乾燥するための組成物および方法 |
| CA3174411A1 (en) | 2020-09-04 | 2022-03-10 | Ryan M. Kramer | Co-lyophilized rna and nanostructured lipid carrier |
| EP4320159A1 (de) | 2021-04-09 | 2024-02-14 | Celldex Therapeutics, Inc. | Antikörper gegen ilt4, bispezifische anti-ilt4/pd-l1-antikörper und verwendungen davon |
| WO2023077521A1 (en) | 2021-11-08 | 2023-05-11 | Celldex Therapeutics, Inc | Anti-ilt4 and anti-pd-1 bispecific constructs |
| WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0288198A3 (de) * | 1987-04-20 | 1989-03-29 | Takeda Chemical Industries, Ltd. | Peptidherstellung |
-
1990
- 1990-07-19 SG SG1996007620A patent/SG48175A1/en unknown
- 1990-07-19 EP EP90307900A patent/EP0414374B1/de not_active Expired - Lifetime
- 1990-07-19 ES ES90307900T patent/ES2109921T3/es not_active Expired - Lifetime
- 1990-07-19 DE DE69031556T patent/DE69031556T2/de not_active Expired - Fee Related
- 1990-07-19 AT AT90307900T patent/ATE159031T1/de not_active IP Right Cessation
- 1990-07-19 DK DK90307900.2T patent/DK0414374T3/da active
- 1990-07-23 IL IL95153A patent/IL95153A0/xx unknown
- 1990-07-23 AU AU59728/90A patent/AU5972890A/en not_active Abandoned
- 1990-07-23 MA MA22181A patent/MA21911A1/fr unknown
- 1990-07-23 PT PT94791A patent/PT94791B/pt not_active IP Right Cessation
- 1990-07-23 CA CA002021762A patent/CA2021762C/en not_active Expired - Fee Related
- 1990-07-23 NZ NZ234615A patent/NZ234615A/xx unknown
- 1990-07-24 NO NO903285A patent/NO304268B1/no not_active IP Right Cessation
- 1990-07-24 IE IE269090A patent/IE902690A1/en unknown
- 1990-07-24 KR KR1019900011386A patent/KR0181940B1/ko not_active IP Right Cessation
- 1990-07-24 FI FI903721A patent/FI903721A0/fi not_active Application Discontinuation
- 1990-07-25 HU HU4615/90A patent/HU216013B/hu not_active IP Right Cessation
- 1990-07-25 CN CN90107172A patent/CN1080304C/zh not_active Expired - Fee Related
- 1990-07-25 PL PL90286209A patent/PL168597B1/pl unknown
- 1990-07-25 JP JP2197578A patent/JP3069907B2/ja not_active Expired - Lifetime
-
1994
- 1994-10-28 AU AU77528/94A patent/AU7752894A/en not_active Abandoned
-
1997
- 1997-04-18 AU AU18968/97A patent/AU714652B2/en not_active Ceased
- 1997-12-30 GR GR970403469T patent/GR3025819T3/el unknown
-
1998
- 1998-03-13 HK HK98102133A patent/HK1003032A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE159031T1 (de) | Antigene sowie verfahren zu deren herstellung | |
| KR880009130A (ko) | 간염 b 바이러스 표면항원 및 이를 함유하는 하이브리드 항원 | |
| ES514712A0 (es) | Procedimiento de preparacion de hb1ag (antigeno superficial de la hepatitis b). | |
| BR0109919A (pt) | Proteìna, partìcula, molécula de ácido nucleico, célula hospedeira, processo para produzir uma proteìna, composição farmacêutica, uso de uma proteìna, e, método de vacinação profilática ou terapêutica de um indivìduo | |
| EP0175261A3 (en) | Hybrid particle immunogens hybrid particle immunogens | |
| FI19992546A (fi) | Hepatiitti B:n S- ja PreS2-proteiinien ilmentäminen metylotrofisissa hiivoissa | |
| NZ206960A (en) | Recombinant antigenic protein containing the amine acid sequence of an epitope of the circumsporozoite protein of a plasmodium species | |
| EP0250253A3 (de) | T- und B-Zellepitopen des pre-S-Gebietes des Hepatitis-B-Oberflächenantigens | |
| ATE73349T1 (de) | Hepatitisoberflaechenantigenpartikelvakzin. | |
| KR920002629A (ko) | B형 간염 코어 항원의 아미노산 잔기 서열 | |
| MY106731A (en) | Novel antigens and methods therefor | |
| DE69133525T8 (de) | Verfahren zur Herstellung von recombinantem Hepatitis B Oberflächenantigen mit erhöhter Immunogen-Kapazität und Verwendung in einer Impfstoffzubereitung | |
| ATE313T1 (de) | Antigenpraeparat verwendbar fuer vakzine oder als zwischenprodukt dafuer und verfahren zu seiner herstellung. | |
| YU45292A (sh) | Različiti površinski proteini hepatitis b virusa koji obrazuju čestice | |
| HK1052368A1 (zh) | 具有源於肝炎e病毒orf2的n末端部分及一抗原多肽加工的編碼成份的核酸結構 | |
| EP0503252A3 (en) | Recombinant proteins having the immunoreactivity of hepatitis b virus e antigens (hbeag), method for their production and their application in immunoassays and as vaccines | |
| DE3475309D1 (en) | Synthetic peptide, immune globulin and process for immunizing a mammal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEIH | Change in the person of patent owner | ||
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |